Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Courtney Nicholas

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
BMJ Oncology|January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancerChad Tang, Genevieve P Hartley, Coline Couillault, et al.
The Lancet. Gastroenterology & Hepatology|January 22, 2022
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trialAhmed Omar Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, et al.
Nature Communications|August 31, 2016
Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediatesVida Chitsazzadeh, Cristian Coarfa, Jennifer A Drummond, et al.
Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
BMJ Oncology|January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancerChad Tang, Genevieve P Hartley, Coline Couillault, et al.
The Lancet. Gastroenterology & Hepatology|January 22, 2022
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trialAhmed Omar Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, et al.
Nature Communications|August 31, 2016
Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediatesVida Chitsazzadeh, Cristian Coarfa, Jennifer A Drummond, et al.
Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Pageof 3